- Home
- GH vs VKTX Comparison
GH vs VKTX Comparison
Compare GH & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GH | VKTX |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 3.8B |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | GH | VKTX |
|---|---|---|
| Price | $97.44 | $34.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 21 | 14 |
| Target Price | ★ $95.29 | $87.07 |
| AVG Volume (30 Days) | 2.3M | ★ 2.7M |
| Earning Date | 10-29-2025 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $902,569,000.00 | N/A |
| Revenue This Year | $34.72 | N/A |
| Revenue Next Year | $26.46 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 30.38 | N/A |
| 52 Week Low | $29.91 | $18.92 |
| 52 Week High | $112.43 | $47.87 |
Technical Indicators
Market Signals| Indicator | GH | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.33 | 40.71 |
| Support Level | $100.21 | $36.49 |
| Resistance Level | $105.01 | $36.38 |
| Average True Range (ATR) | 4.21 | 1.91 |
| MACD | -1.89 | -0.39 |
| Stochastic Oscillator | 9.53 | 3.88 |
Price Performance
Historical ComparisonAbout GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.